Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “purchase” ranking to a “hold” rating in a research note released to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on uncovering and developing tiny molecule drug prospects to treat cancer cells. The Firm‘s products under various phases of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts also just recently talked about the company. Noble Financial editioned a “purchase” ranking and issued a $11.00 rate objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating average price of $2.90 and also a two-hundred day relocating typical rate of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, covering experts’ agreement quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an adverse web margin of 8,294.27%. The firm had income of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Throughout the very same quarter in the previous year, the company uploaded ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will post -1.18 EPS for the present year.

A number of hedge funds have actually lately bought and sold shares of ONTX. GSA Resources Partners LLP got a new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Administration LP acquired a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional capitalists own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification as well as development of oncology therapeutics. It focuses on finding and developing small particle medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more information regarding research offerings from Zacks Investment Research, visit Zacks.com.

This instant information alert was created by narrative scientific research innovation as well as financial data from Market in order to provide viewers with the fastest and most precise coverage. This tale was reviewed by Market’s content team before magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you think about Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s premier and finest carrying out research experts and also the stocks they suggest to their clients every day. Market has identified the 5 stocks that top experts are quietly murmuring to their clients to get currently before the broader market catches on … and also Onconova Therapeutics had not been on the list.

While Onconova Therapeutics presently has a “Buy” rating among experts, top-rated analysts think these 5 stocks are much better buys.